<?xml version="1.0" encoding="UTF-8"?>
<p>Therefore, from a theoretical standpoint, ACEi and ARBs might facilitate viral entry into respiratory cells leading to viral mediated cell damage, but on the other hand, these same medications might upregulate ACE2 and ameliorate the acute lung injury caused by the virus. It is not clear which of these activities are predominant in individuals with COVID‐19 and further research is needed. In the meantime, most current cardiology guidelines recommend that patients on ACEi and ARBs should continue taking their medications as usual an should not discontinue them with CoVID‐19 disease.
 <xref rid="clc23406-bib-0036" ref-type="ref">
  <sup>36</sup>
 </xref>
</p>
